Premium
Dendritic Glycopolymer as Drug Delivery System for Proteasome Inhibitor Bortezomib in a Calcium Phosphate Bone Cement: First Steps Toward a Local Therapy of Osteolytic Bone Lesions
Author(s) -
Striegler Christin,
Schumacher Matthias,
Effenberg Christiane,
Müller Martin,
Seckinger Anja,
Schnettler Reinhard,
Voit Brigitte,
Hose Dirk,
Gelinsky Michael,
Appelhans Dietmar
Publication year - 2015
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201500085
Subject(s) - drug delivery , biocompatibility , chemistry , glycopolymer , calcium , bortezomib , proteasome inhibitor , bone cement , drug , biophysics , pharmacology , materials science , biochemistry , cement , proteasome , polymer , medicine , organic chemistry , immunology , composite material , multiple myeloma , copolymer , biology
Establishment of drug delivery system (DDS) in bone substitute materials for local treatment of bone defects still requires ambitious solutions for a retarded drug release. We present two novel DDS, a weakly cationic dendritic glycopolymer and a cationic polyelectrolyte complex, composed of dendritic glycopolymer and cellulose sulfate, for the proteasome inhibitor bortezomib. Both DDS are able to induce short‐term retarded release of bortezomib from calcium phosphate bone cement in comparison to a burst‐release of the drug from bone cement alone. Different release parameters have been evaluated to get a first insight into the release mechanism from bone cements. In addition, biocompatibility of the calcium phosphate cement, modified with the new DDS was investigated using human mesenchymal stromal cells.